drugset
drugset / Trial / NCT05842798

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults

NCT05842798 ↗

Phase 1 Completed 28 enrolled Zhuhai Trinomab Pharmaceutical Co., Ltd.
RandomizedSequentialTriple-blindPrevention

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics properties of TNM002 following a single intramuscular dose in Chinese healthy adults.

Timeline

Start
2021-10-15
Primary completion
2022-02-24
Completion
2022-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject SILTARTOXATUG Monoclonal antibody 35 ug/kg Intramuscular
Subject SILTARTOXATUG Monoclonal antibody 100 ug/kg Intramuscular
Subject SILTARTOXATUG Monoclonal antibody 250 ug/kg Intramuscular

Indications

No indication recorded.